Dissenting Statement of Commissioner Rohit Chopra Joined by Commissioner Rebecca Kelly Slaughter in the Matter of Pfizer Inc./Mylan N.V.
Date
By
Rohit Chopra, Former Commissioner
Matter Number
191 0182
Displaying 21 - 33 of 33
FTC to Hold Workshop on Examining Competition Issues Related to Prescription Drug Markets
Date
WHAT: The Federal Trade Commission will host a workshop, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics” . Acting FTC Chairman Maureen K. Ohlhausen and U.S...
FTC Staff Issues FY 2015 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
Date
The number of reverse-payment patent settlements entered into by pharmaceutical companies in fiscal year 2015 declined from fiscal year 2014, marking a second annual decrease in such settlements...
FTC Announces Agenda for November 8 Workshop on Examining Competition Issues Related to Prescription Drug Markets
Date
The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in...
FTC to Conduct Workshop on November 8, Examining Competition Issues Related to Prescription Drug Markets
Date
The Federal Trade Commission will hold a workshop on November 8, 2017 entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K...
FTC Announces Agenda for Workshop Examining Competition Issues Surrounding Biologic and Follow-on Biologic Medicines: Biosimilars and Interchangeables
Date
The Federal Trade Commission has announced the agenda for the upcoming public roundtable on “Follow-on Biologics: Impact of Recent Legislative and Regulatory Naming Proposals on Competition.” The...
FTC to Host Workshop on the Competitive Impacts of State Regulations and Naming Conventions Concerning Follow-on Biologics
Date
The Federal Trade Commission will host a one-day public workshop on December 10, 2013, at its headquarters in Washington, DC, to examine competition issues surrounding biologic and follow-on biologic...
FTC Extends the Deadlines for Public Comments on 13 Matters Before the Agency
Date
In light of the recent, temporary government shutdown, the Federal Trade Commission is extending the public comment periods for 13 matters that currently are pending before the agency in order to...
FTC Submits Proposed Amicus Brief Concerning “No-Authorized-Generic” Commitments in Drug Companies’ Patent Settlements
Date
The Federal Trade Commission has asked the U.S. District Court for the District of New Jersey to accept an amicus brief that addresses the application of the U.S. Supreme Court’s recent ruling in FTC...
Announced Action for April 7, 2005
Date
Commission response to Food and Drug Administration citizen petition: The Commission has authorized the submission of a response to the U.S. Food and Drug Administration (FDA) regarding a citizen...
Generic Drug Marketers Settle FTC Charges
Date
Generic drug manufacturers Alpharma, Inc. and Perrigo Company will give up $6.25 million in illegal profits to settle Federal Trade Commission charges that their agreement to limit competition for...
Report
Generic Drug Entry Prior to Patent Expiration: An FTC Study
Date
File
Text of the Report
(3.01 MB)
Mylan, Nation's Second Largest Generic Drug Maker, Charged with Restraint of Trade, Conspiracy & Monopolization
Date
Mylan Laboratories, Inc., the nation’s second largest generic drug manufacturer, and three other companies, were charged today by the Federal Trade Commission with restraint of trade, monopolization...
Displaying 21 - 33 of 33